|
Jul 29
|
All You Need to Know About Genmab (GMAB) Rating Upgrade to Strong Buy
|
|
Jul 25
|
GMAB vs. CSLLY: Which Stock Is the Better Value Option?
|
|
Jul 8
|
GMAB vs. TECH: Which Stock Is the Better Value Option?
|
|
Jun 27
|
Completion of Share Buy-back Program
|
|
Jun 27
|
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma
|
|
Jun 26
|
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
|
|
May 6
|
Transactions in Connection with Share Buy-back Program
|
|
Jan 9
|
GMAB or TECH: Which Is the Better Value Stock Right Now?
|
|
Jan 9
|
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
|
|
Jan 9
|
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
|
|
Jan 3
|
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
|
|
Jan 2
|
Genmab to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 9
|
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
|
|
Dec 9
|
New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
|
|
Dec 7
|
HRMY or GMAB: Which Is the Better Value Stock Right Now?
|
|
Dec 5
|
Capital Increase in Genmab as a Result of Employee Warrant Exercise
|
|
Nov 28
|
AbbVie (ABBV) Lymphoma Drug Gets FDA Breakthrough Therapy Tag
|
|
Nov 27
|
Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
|
|
Aug 24
|
Nvidia upgraded, Estee Lauder downgraded: Wall Street's top analyst calls
|